Literature DB >> 24437088

Twenty years of immunocontraceptive research: lessons learned.

Lowell A Miller1, Kathleen A Fagerstone1, Douglas C Eckery1.   

Abstract

The National Wildlife Research Center (NWRC) began immunocontraception vaccine research by testing porcine zona pellucida (PZP) on white-tailed deer (Odocoileus virginianus). Early PZP research demonstrated that PZP induced infertility; however, increased length of the rut was observed in PZP-treated deer. An alternative vaccine using a keyhole limpet hemocyanin-gonadotropin-releasing hormone (KLH-GnRH) conjugate formulated with modified Freund's adjuvant was developed at NWRC. Suppression of GnRH has reduced reproduction in both sexes but is most effective in females. This vaccine was effective in preventing contraception in female deer for several years after a prime and boost. Due to adverse side effects of Freund's adjuvant, NWRC developed a new adjuvant called AdjuVac, a mineral oil/surfactant adjuvant with the addition of Mycobacterium avium as an immunostimulant. The price of KLH prompted a search for a more economical hemocyanin carrier protein for the GnRH peptide. Blue protein, derived from the mollusk Concholepas concholepas, proved to be a successful option. Formulation improvements resulted in a vaccine that can be effective as a single injection for multiple years, now called GonaCon. GonaCon is registered with the Environmental Protection Agency (EPA) for use in white-tailed deer in urban/suburban areas and for wild horses (Equus caballus) and burros (Equus asinus). Future GonaCon applications may include reducing reproduction to manage populations of other wildlife species, such as prairie dogs (Cynomys ludovicianus) in urban areas and suppressing reproduction to reduce the spread of venereal diseases such as brucellosis. Research is being conducted to develop a GnRH vaccine used in combination with the rabies vaccine to control population growth in free-roaming dogs, with the secondary effect of managing the spread of rabies. The EPA would regulate all these uses. Research is also ongoing on a GnRH vaccine to delay the onset of adrenocortical disease in pet ferrets (Mustela putorius), a use regulated by the United States Department of Agriculture.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24437088     DOI: 10.1638/1042-7260-44.4S.S84

Source DB:  PubMed          Journal:  J Zoo Wildl Med        ISSN: 1042-7260            Impact factor:   0.776


  6 in total

1.  Reproductive immunology issue one: cellular and molecular biology.

Authors:  B Anne Croy
Journal:  Cell Mol Immunol       Date:  2014-07-28       Impact factor: 11.530

2.  Potential effects of incorporating fertility control into typical culling regimes in wild pig populations.

Authors:  Kim M Pepin; Amy J Davis; Fred L Cunningham; Kurt C VerCauteren; Doug C Eckery
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

3.  Overabundance of sika deer and immunocontraception.

Authors:  Junko Noguchi
Journal:  J Reprod Dev       Date:  2016-11-28       Impact factor: 2.214

4.  Reimmunization increases contraceptive effectiveness of gonadotropin-releasing hormone vaccine (GonaCon-Equine) in free-ranging horses (Equus caballus): Limitations and side effects.

Authors:  Dan L Baker; Jenny G Powers; Jason I Ransom; Blake E McCann; Michael W Oehler; Jason E Bruemmer; Nathan L Galloway; Douglas C Eckery; Terry M Nett
Journal:  PLoS One       Date:  2018-07-31       Impact factor: 3.240

5.  Inactivated Rabies Virus-Vectored Immunocontraceptive Vaccine in a Thermo-Responsive Hydrogel Induces High and Persistent Antibodies against Rabies, but Insufficient Antibodies against Gonadotropin-Releasing Hormone for Contraception.

Authors:  Xianfu Wu; Yong Yang; Chantal Kling; Laurie Seigler; Nadia F Gallardo-Romero; Brock E Martin; Todd G Smith; Victoria A Olson
Journal:  Vaccines (Basel)       Date:  2019-07-25

6.  Effect of vaccination with a novel GnRH-based immunocontraceptive on immune responses and fertility in rats.

Authors:  G Massei; D Cowan; D Eckery; R Mauldin; M Gomm; P Rochaix; F Hill; R Pinkham; L A Miller
Journal:  Heliyon       Date:  2020-04-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.